ライフサイエンスコーパス: viraemia

1 a detectable viral load (local prevalence of viraemia).

2 T cells and the rapid reappearance of plasma viraemia.

3 wed by a slower second-phase decay of plasma viraemia.

4 ion of HIV-positive partners with detectable viraemia.

5 ties with an at least 5% local prevalence of viraemia.

6 th-care providers 6 weeks after clearance of viraemia.

7 h higher ranges and persistence of low-level viraemia.

8 o ART strongly predict time to the return of viraemia.

9 Two patients receiving ART had transient HIV viraemia.

10 ection of rhesus monkeys and before systemic viraemia.

11 g the 'eclipse' phase, and before detectable viraemia.

12 seroconversion and extended the duration of viraemia.

13 IV dissemination and strongly reduced plasma viraemia.

14 lated significantly with reduced acute phase viraemia.

15 y has a role in reduction of cytomegalovirus viraemia.

16 t HCMV serostatus was also a risk factor for viraemia.

17 dren, resulting in antigenaemia and possible viraemia.

18 infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk b

19 -week 24 was spent with persistent low-level viraemia (80-5,000 copies/ml) and 10% with VL rebound >/

20 0001), and summed PET signal correlated with viraemia across a 4 log range (r2=0.98, p<0.0001).

21 -1 gag/pol/nef vaccine did not reduce plasma viraemia after infection, and HIV-1 incidence was higher

22 In those who developed viraemia after transplantation, glycoprotein-B antibody

23 ction in mice and non-human primates against viraemia after Zika virus challenge.

24 Here we show that, despite rebound in viraemia, all subjects were able to achieve at least a t

25 tential HIV transmission risk and detectable viraemia among serodiscordant couples warrant intensifie

26 High fever, viraemia and abnormalities in blood count and blood chem

27 0% survival, even when initiated when fever, viraemia and disease signs were evident.

28 combination antiretroviral therapy (ART) on viraemia and immune responses, sexual risk behaviour, an

29 occurrence and recurrence of cytomegalovirus viraemia and improved the time-to-event for viraemia epi

30 d that identify protection as the absence of viraemia and the absence of an anamnestic antibody respo

31 rol coincides with a final escalation of the viraemia and the terminal failure of the immune system.

32 A more than 150 copies per mL (prevalence of viraemia); and the proportion of participants with HIV w

33 Immunogenicity, viraemia, and shedding post-vaccination were evaluated a

34 C117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a

35 lonal antibodies have been shown to suppress viraemia, but the therapeutic potential of these monoclo

36 onic long-term HIV-1 patients who had stable viraemia by RT-PCR (non-progressors).

37 For participants with undetectable viraemia by TaqMan, there was poor concordance without c

38 proximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and bo

39 al immunity by vaccination might achieve CMV viraemia control without the need for antiviral agents.

40 eles of the B58 supertype associate with low viraemia, delayed onset of AIDS and, possibly, cytotoxic

41 nst all four dengue virus serotypes, and the viraemia due to each of the four vaccine components afte

42 time to viral rebound correlated with total viraemia during acute infection and with proviral DNA at

43 We investigated the occurrence of detectable viraemia during ART below this threshold and its effect

44 viraemia and improved the time-to-event for viraemia episodes compared with placebo.

45 a single treatment rapidly suppressed plasma viraemia for 3-5 weeks in some long-term chronically SHI

46 er half-life of antibodies led to control of viraemia for an average of 60 days after cessation of th

47 er vector competence and shorter duration of viraemia for SBV compared with BTV.

48 Our primary endpoint was any viraemia greater than 50 copies per mL.

49 Prevalence of viraemia had the strongest correlation with HIV incidenc

50 the community programme, shorter duration of viraemia, higher CD4 count and transfers into programme

51 workplace patients had a longer duration of viraemia, higher VL, lower CD4 count, and higher reporte

52 e failure of ART with a lenient threshold of viraemia (HIV RNA viral load >/=1000 copies per mL).

53 ximal leakage occurs several days after peak viraemia implicating immunological pathways.

54 aphical locations with high-level detectable viraemia in east Africa.

55 ntibodies can prevent infection and suppress viraemia in humanized mice and nonhuman primates, but th

56 heir ability to block infection and suppress viraemia in macaques infected with the R5 tropic simian-

57 viral load-the approximately stable value of viraemia in the first years of chronic infection-is a st

58 accine (TransVax) for clinically significant viraemia in the HSCT setting.

59 ompared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-mon

60 We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV

61 Cytomegalovirus viraemia is associated with an increased risk of overall

62 can be prevented by giving ganciclovir when viraemia is detected in allograft recipients.

63 TTV viraemia is frequent in the blood-donor population, and

64 Strategies for management of low-level viraemia need to be incorporated into WHO guidelines to

65 e we show that sudden breakthrough of plasma viraemia occurred after prolonged immune containment in

66 ERPRETATION: In this large cohort, low-level viraemia occurred frequently and increased the risk of v

67 Low-level viraemia occurred in 16 013 (23%) of 69 454 patients, wi

68 A low-level, transient, dose-dependent viraemia occurred in concert with early reactogenicity.

69 gical failure--which we defined as confirmed viraemia of more than 1000 copies per mL--in the switch

70 mpromised local viral retention, exacerbated viraemia of the host, and impaired local B-cell activati

71 mice infected with HCV results in measurable viraemia over several weeks.

72 nset delayed, reflecting significantly lower viraemia (p<0.0001) and blood monocyte-activation patter

73 titres correlated inversely with duration of viraemia (p=0.0022).

74 ts with seropositive donors, the duration of viraemia (p=0.0480) and number of days of ganciclovir tr

75 CD4 antigen (CD4(+)) and very low levels of viraemia persisted for over 2 years.

76 oss-reactive antibodies prolonged YF vaccine viraemia, provoked greater pro-inflammatory responses, a

77 -1-infected individuals by 0.8-2.5 log10 and viraemia remained significantly reduced for 28 days.

78 Viraemia remained undetectable for 56-177 days, dependin

79 We have investigated whether cytomegalovirus viraemia remains a significant risk factor for progressi

80 ent control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped.

81 he occurrence rate of clinically significant viraemia resulting in initiation of cytomegalovirus-spec

82 Many children with detectable low-level viraemia spontaneously resuppressed, highlighting the im

83 BTV infection of ruminants results in a high viraemia, suggesting that repeated sharing of needles be

84 on, and tight correlation of PET signal with viraemia suggests target-cell activation determines stea

85 fections are characterized by early peaks of viraemia that decline as strong cellular immune response

86 characterized by: occasional blips of plasma viraemia that ultimately waned; predominantly undetectab

87 on dynamics showed that the duration of HCMV viraemia, the peak viral load, and the growth rate of HC

88 gh the Zika virus (ZIKV) rapidly establishes viraemia, the target cells and immune responses, particu

89 in a rapid and precipitous decline of plasma viraemia to undetectable levels in rhesus monkeys chroni

90 We tested for viraemia, undertook analyses for haematology and serum b

91 This sudden increase in viraemia was associated with a decline in half of the CD

92 Low-level viraemia was associated with increased hazards of virolo

93 Low-level viraemia was defined as the occurrence of at least one v

94 TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerat

95 g resting CD4(+) T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy,

96 Enterovirus D68 viraemia was identified in a child experiencing acute ne

97 HIV-positive mothers who cleared the virus, viraemia was intermittent.

98 Prevalence of viraemia was more strongly correlated with HIV incidence

99 ection, experienced sustained rebound plasma viraemia when treatment was interrupted.

100 ssociated with very low levels of persistent viraemia, which leads to the establishment of T-cell imm

101 s in epitopes associated with suppression of viraemia will accumulate as the epidemic progresses, and

102 Panobinostat induced plasma viraemia with an odds ratio of 10.5 (95% CI 2.2-50.3; p

103 setting, few data are available correlating viraemia with clinical endpoints.

104 hown to reduce the magnitude and duration of viraemia with re-challenge.

105 uick and accurate approach for assessing HIV viraemia, with excellent concordance with validated labo

106 rcentage point in a community, prevalence of viraemia would need to be reduced by 4.34%, and ART use

107 NA and are rapidly eliminated at the peak of viraemia, yet the mechanism by which HIV-1 induces helpe